AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

The stock's fall snapped a two-day winning streak.

If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...

AbbVie Inc.’s TV advertisements featuring tennis legend Serena Williams make misleading claims about the effectiveness of its ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $196.42 which represents a slight increase of $3.02 or 1.56% from the prior close of $193.4. The stock opened at $194.97 and touched a ...

We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...

As with many other companies AbbVie Inc. (NYSE:ABBV) makes use of debt. But should shareholders be worried about its use of debt? Debt is a tool to help businesses grow, but if a business is incapable ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...